The KRAS mutation has been reported to be the most frequently mutated oncogene in human tumours and has been the investigative target in many cancer studies specifically in colorectal, pancreatic and in non-small lung cancers (Kim et al. 2018; Kuboki et al. 2019; Roerink et al. 2018; Román et al. 2018). Here, KRAS is linked to cancer.